



# J. B. CHEMICALS & PHARMACEUTICALS LIMITED

February 14, 2022

BSE Ltd.  
Phiroze Jeejeebhoy Towers  
Dalal Street  
Mumbai 400 001

**BSE Scrip Code: 506943**

**Stock Symbol: JBCHEPHARM**

Dear Sir,

**Sub: Outcome of meeting of Board of Directors – Unaudited Financial Results for the quarter ended December 31, 2021**

In compliance with Regulation 30(2) and Regulation 33(3) of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 read with circular no. CIR/CFD/CMD/4/2015 dated September 09, 2015, enclosed please find:

1. Unaudited standalone financial results for the quarter ended on December 31, 2021 accompanied by limited review report.
2. Unaudited consolidated financial results for the quarter ended on December 31, 2021 accompanied by limited review report.

These financial results have been approved and taken on record by the Board of Directors at its meeting held today, which commenced at 4.15 p.m. and concluded at 5:43 p.m.

We request you to take the above on record.

Thanking you,


Yours faithfully,  
**For J.B. Chemicals & Pharmaceuticals Ltd.**

**Sandeep Phadnis**  
**Vice President - Secretarial**  
**& Company Secretary**

**Registered Office:**  
Neelam Centre, B Wing, 4th Floor  
Hind Cycle Road, Worli  
Mumbai - 400 030

**Corporate Office:**  
Cnergy IT Park  
Unit A2, 3rd Floor, Unit A, 8th Floor  
Appa Saheb Marathe Marg, Prabhadevi  
Mumbai - 400 025

**☎ +91 22 2439 5200 / 2439 5500**  
**☎ +91 22 2431 5331 / 2431 5334**  
**@ info@jbcpl.com**  
**@ www.jbcpl.com**  
**CIN: L24390MH1976PLC019380**



# J. B. CHEMICALS & PHARMACEUTICALS LIMITED

STATEMENT OF STANDALONE UNAUDITED FINANCIAL RESULTS FOR THE QUARTER AND NINE MONTHS ENDED 31ST DECEMBER, 2021

(₹ in lakhs)

Particulars	Quarter ended			Nine months ended		Year ended
	31/12/2021	30/09/2021	31/12/2020	31/12/2021	31/12/2020	31/03/2021
	Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited
1. Revenue from operations	53,327.22	52,672.69	50,034.14	1,60,630.04	1,40,174.42	1,89,199.55
2. Other income (Refer note 3)	431.45	1,956.07	5,586.24	3,675.75	8,658.56	11,188.94
3. Total income (1+2)	53,758.67	54,628.76	55,620.38	1,64,305.79	1,48,832.98	2,00,388.49
4. Expenses						
a) Cost of materials consumed	14,655.96	14,707.66	12,856.23	44,151.42	40,718.64	54,216.52
b) Purchases of stock-in-trade	2,378.14	5,031.75	1,932.62	12,354.64	7,527.73	9,929.08
c) Changes in inventories of finished goods, work-in-progress and stock-in-trade	958.45	(1,752.04)	1,782.63	(2,003.28)	(3,046.49)	(1,570.03)
d) Employee benefits expense (Refer note 4)	10,864.52	9,521.95	7,496.65	29,262.03	22,953.68	30,597.97
e) Finance costs	130.16	118.44	108.18	337.14	650.89	719.18
f) Depreciation and amortisation expense	1,661.80	1,539.94	1,705.54	4,949.61	5,116.28	6,735.50
g) Other expenses	13,036.21	13,695.02	9,305.78	38,132.52	28,971.46	40,389.47
Total expenses	43,685.24	42,862.72	35,187.63	1,27,184.08	1,02,892.19	1,41,017.69
5. Profit before tax (3-4)	10,073.43	11,766.04	20,432.75	37,121.71	45,940.79	59,370.80
6. Tax expense						
a) Current tax	2,650.00	2,700.00	4,800.00	9,150.00	10,900.00	13,750.00
b) Deferred tax	(33.70)	226.05	465.96	143.38	583.16	912.32
Total tax expense	2,616.30	2,926.05	5,265.96	9,293.38	11,483.16	14,662.32
7. Net profit after tax (5-6)	7,457.13	8,839.99	15,166.79	27,828.33	34,457.63	44,708.48
8. Other comprehensive income						
a) (i) Items that will not be reclassified to profit or loss	(210.00)	(211.43)	(724.63)	(633.98)	(1,336.07)	(1,669.97)
(ii) Income tax on items that will not be reclassified to profit or loss	52.85	53.22	182.37	159.56	336.26	420.30
b) (i) Items that will be reclassified to profit or loss	133.20	-	-	133.20	-	-
(ii) Income tax on items that will be reclassified to profit or loss	(33.51)	-	-	(33.51)	-	-
Total other comprehensive income (net of tax)	(57.46)	(158.21)	(542.26)	(374.73)	(999.81)	(1,249.67)
9. Total comprehensive income (7+8)	7,399.67	8,681.78	14,624.53	27,453.60	33,457.82	43,458.81
10. Paid-up equity share capital (face value ₹ 2/- each)	1,545.64	1,545.64	1,545.64	1,545.64	1,545.64	1,545.64
11. Other equity						1,79,100.45
12. Earnings per share (face value ₹ 2/- each)						
a) Basic (₹)	*9.65	*11.44	*19.63	*36.01	*44.59	57.85
b) Diluted (₹)	*9.63	*11.42	*19.63	*35.93	*44.59	57.85
*Not Annualised						

Registered Office:  
Neelam Centre, B Wing, 4th Floor  
Hind Cycle Road, Worli  
Mumbai - 400 030

Corporate Office:  
Energy IT Park 1/2  
Unit A2, 3rd Floor, Unit A, 8th Floor  
Appa Saheb Marathe Marg, Prabhadevi  
Mumbai - 400 025

+91 22 2439 5200 / 2439 5500  
+91 22 2431 5331 / 2431 5334  
info@jbcpl.com  
www.jbcpl.com  
CIN: L24390MH1976PLC019380



# J. B. CHEMICALS & PHARMACEUTICALS LIMITED

## Notes:

1. The above standalone financial results have been reviewed and recommended to the Board of Directors by the Audit Committee and subsequently approved by the Board of Directors at their respective meetings held on 14th February, 2022. These results have been subjected to Limited review by the Statutory auditors of the Company. The results of the Company are available for investors at [www.jbcpl.com](http://www.jbcpl.com), [www.nseindia.com](http://www.nseindia.com) and [www.bseindia.com](http://www.bseindia.com).
2. These financial results have been prepared in accordance with the recognition and measurement principles laid down in the Companies (Indian Accounting Standards) Rules 2015 (as amended) ('Ind AS') prescribed under Section 133 of the Companies Act, 2013 read with relevant rules thereunder and in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended).
3. Other income for the year ended March 31, 2021 includes ₹1,977.24 lakhs being net profit on sale of an industrial land in the state of Maharashtra and ₹3,368.66 lakhs being consideration towards sale of one of the Company's product registration along with its marketing authorisation and trademark.
4. During the quarter, the Company has granted 2,06,463 stock options (comprising of 1,21,095 performance based stock options and 85,368 time based stock options) to employees of the Company/ subsidiary Company. With these grants the total options granted stand at 28,10,721 stock options (comprising of 15,72,761 performance based stock options and 12,37,960 time based stock options) to employees and whole-time director(s) of the Company/ subsidiary company. The employee benefits expense for the quarters ended December 31, 2021 and September 30, 2021 and for the nine months ended December 31, 2021 includes charge of ₹2,416 lakhs, ₹1,316 lakhs and ₹3,732 lakhs respectively, towards equity-settled share-based payment transactions in terms of Ind AS 102 - 'Share-based Payment'.
5. Non-adjusting event subsequent to the reporting period: On January 25, 2022, the Board of Directors of the Company approved the acquisition of a portfolio of brands, for use and commercialisation within India, from Sanzyme Private Limited . The transaction was completed on February 1, 2022.
6. The Board of Directors, at its meeting held today, have declared an interim dividend of ₹8.50 per equity share of ₹2 each for the year 2021-22. The record date fixed for the purpose of ascertaining the entitlement is February 24, 2022.
7. Based on the internal and external information available up to the date of approval of these financial results by the Board of Directors, the Company continues to believe that the impact of Covid-19 on its business, assets, internal financial controls, profitability and liquidity, both present and future, would be limited and there is no indication of any material impact on the carrying amounts of inventories, tangible and intangible assets, investments, trade receivables and other financial assets. However, concerns of Covid-19 pandemic still continue and hence, the Company continues to follow necessary safety guidelines. The eventual outcome of the impact of the global health pandemic may be different from those estimated as on the date of approval of these financial results and the management will continue to closely monitor the changes to economic conditions in future and its impact on the Company.
8. The Company has only one reportable business segment viz. "Pharmaceuticals".
9. The figures for the previous period(s) have been re-grouped/reclassified, wherever necessary.

Mumbai  
14th February, 2022

By order of the Board  
For J.B. Chemicals & Pharmaceuticals Limited



Nikhil Chopra

Chief Executive Officer & Whole-time Director

### Registered Office:

Neelam Centre, B Wing, 4th Floor  
Hind Cycle Road, Worli  
Mumbai - 400 030

### Corporate Office:

Energy IT Park 2/2  
Unit A2, 3rd Floor, Unit A, 8th Floor  
Appa Saheb Marathe Marg, Prabhadevi  
Mumbai - 400 025

+91 22 2439 5200 / 2439 5500

+91 22 2431 5331 / 2431 5334

info@jbcpl.com

www.jbcpl.com

CIN: L24390MH1976PLC019380



**INDEPENDENT AUDITOR'S REVIEW REPORT ON REVIEW OF INTERIM  
STANDALONE FINANCIAL RESULTS**

**TO THE BOARD OF DIRECTORS OF  
J. B. CHEMICALS & PHARMACEUTICALS LIMITED**

1. We have reviewed the accompanying Statement of Standalone Unaudited Financial Results of **J. B. CHEMICALS & PHARMACEUTICALS LIMITED** ("the Company"), for the quarter and nine months ended December 31, 2021 ("the Statement"), being submitted by the Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended.
2. This Statement, which is the responsibility of the Company's Management and approved by the Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other accounting principles generally accepted in India. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 'Review of Interim Financial Information Performed by the Independent Auditor of the Entity', issued by the Institute of Chartered Accountants of India (ICAI). A review of interim financial information consists of making inquiries, primarily of the Company's personnel responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing specified under Section 143(10) of the Companies Act, 2013 and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.
4. Based on our review conducted as stated in paragraph 3 above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standard and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, including the manner in which it is to be disclosed, or that it contains any material misstatement.

For DELOITTE HASKINS & SELLS LLP  
Chartered Accountants  
(Firm's Registration No. 117366W/W-100018)



Rajesh K. Hiranandani  
Partner  
(Membership No.36920)  
(UDIN: 22036920ACAAXV1853)

EA

Place: MUMBAI  
Date: February 14, 2022





# J. B. CHEMICALS & PHARMACEUTICALS LIMITED

STATEMENT OF STANDALONE UNAUDITED FINANCIAL RESULTS FOR THE QUARTER AND NINE MONTHS ENDED 31ST DECEMBER, 2021

(₹ in lakhs)

Particulars	Quarter ended			Nine months ended		Year ended
	31/12/2021	30/09/2021	31/12/2020	31/12/2021	31/12/2020	31/03/2021
	Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited
1. Revenue from operations	53,327.22	52,672.69	50,034.14	1,60,630.04	1,40,174.42	1,89,199.55
2. Other income (Refer note 3)	431.45	1,956.07	5,586.24	3,675.75	8,658.56	11,188.94
3. Total income (1+2)	53,758.67	54,628.76	55,620.38	1,64,305.79	1,48,832.98	2,00,388.49
4. Expenses						
a) Cost of materials consumed	14,655.96	14,707.66	12,856.23	44,151.42	40,718.64	54,216.52
b) Purchases of stock-in-trade	2,378.14	5,031.75	1,932.62	12,354.64	7,527.73	9,929.08
c) Changes in inventories of finished goods, work-in-progress and stock-in-trade	958.45	(1,752.04)	1,782.63	(2,003.28)	(3,046.49)	(1,570.03)
d) Employee benefits expense (Refer note 4)	10,864.52	9,521.95	7,496.65	29,262.03	22,953.68	30,597.97
e) Finance costs	130.16	118.44	108.18	337.14	650.89	719.18
f) Depreciation and amortisation expense	1,661.80	1,539.94	1,705.54	4,949.61	5,116.28	6,735.50
g) Other expenses	13,036.21	13,695.02	9,305.78	38,132.52	28,971.46	40,389.47
Total expenses	43,685.24	42,862.72	35,187.63	1,27,184.08	1,02,892.19	1,41,017.69
5. Profit before tax (3-4)	10,073.43	11,766.04	20,432.75	37,121.71	45,940.79	59,370.80
6. Tax expense						
a) Current tax	2,650.00	2,700.00	4,800.00	9,150.00	10,900.00	13,750.00
b) Deferred tax	(33.70)	226.05	465.96	143.38	583.16	912.32
Total tax expense	2,616.30	2,926.05	5,265.96	9,293.38	11,483.16	14,662.32
7. Net profit after tax (5-6)	7,457.13	8,839.99	15,166.79	27,828.33	34,457.63	44,708.48
8. Other comprehensive income						
a) (i) Items that will not be reclassified to profit or loss	(210.00)	(211.43)	(724.63)	(633.98)	(1,336.07)	(1,669.97)
(ii) Income tax on items that will not be reclassified to profit or loss	52.85	53.22	182.37	159.56	336.26	420.30
b) (i) Items that will be reclassified to profit or loss	133.20	-	-	133.20	-	-
(ii) Income tax on items that will be reclassified to profit or loss	(33.51)	-	-	(33.51)	-	-
Total other comprehensive income (net of tax)	(57.46)	(158.21)	(542.26)	(374.73)	(999.81)	(1,249.67)
9. Total comprehensive income (7+8)	7,399.67	8,681.78	14,624.53	27,453.60	33,457.82	43,458.81
10. Paid-up equity share capital (face value ₹ 2/- each)	1,545.64	1,545.64	1,545.64	1,545.64	1,545.64	1,545.64
11. Other equity						1,79,100.45
12. Earnings per share (face value ₹ 2/- each)						
a) Basic (₹)	*9.65	*11.44	*19.63	*36.01	*44.59	57.85
b) Diluted (₹)	*9.63	*11.42	*19.63	*35.93	*44.59	57.85

EM RKU

Registered Office:  
Neelam Centre, B Wing, 4th Floor  
Hind Cycle Road, Worli  
Mumbai - 400 030

Corporate Office:  
Energy IT Park 1/2  
Unit A2, 3rd Floor, Unit A, 8th Floor  
Appa Saheb Marathe Marg, Prabhadevi  
Mumbai - 400 025

+91 22 2439 5200 / 2439 5500  
+91 22 2431 5331 / 2431 5334  
info@jbcpi.com  
www.jbcpi.com  
CIN: L24390MH1976PLC019380



# J. B. CHEMICALS & PHARMACEUTICALS LIMITED

## Notes:

1. The above standalone financial results have been reviewed and recommended to the Board of Directors by the Audit Committee and subsequently approved by the Board of Directors at their respective meetings held on 14th February, 2022. These results have been subjected to Limited review by the Statutory auditors of the Company. The results of the Company are available for investors at [www.jbcpl.com](http://www.jbcpl.com), [www.nseindia.com](http://www.nseindia.com) and [www.bseindia.com](http://www.bseindia.com).
2. These financial results have been prepared in accordance with the recognition and measurement principles laid down in the Companies (Indian Accounting Standards) Rules 2015 (as amended) ('Ind AS') prescribed under Section 133 of the Companies Act, 2013 read with relevant rules thereunder and in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended).
3. Other income for the year ended March 31, 2021 includes ₹1,977.24 lakhs being net profit on sale of an industrial land in the state of Maharashtra and ₹3,368.66 lakhs being consideration towards sale of one of the Company's product registration along with its marketing authorisation and trademark.
4. During the quarter, the Company has granted 2,06,463 stock options (comprising of 1,21,095 performance based stock options and 85,368 time based stock options) to employees of the Company/ subsidiary Company. With these grants the total options granted stand at 28,10,721 stock options (comprising of 15,72,761 performance based stock options and 12,37,960 time based stock options) to employees and whole-time director(s) of the Company/ subsidiary company. The employee benefits expense for the quarters ended December 31, 2021 and September 30, 2021 and for the nine months ended December 31, 2021 includes charge of ₹2,416 lakhs, ₹1,316 lakhs and ₹3,732 lakhs respectively, towards equity-settled share-based payment transactions in terms of Ind AS 102 - 'Share-based Payment'.
5. Non-adjusting event subsequent to the reporting period: On January 25, 2022, the Board of Directors of the Company approved the acquisition of a portfolio of brands, for use and commercialisation within India, from Sanzyme Private Limited. The transaction was completed on February 1, 2022.
6. The Board of Directors, at its meeting held today, have declared an interim dividend of ₹8.50 per equity share of ₹2 each for the year 2021-22. The record date fixed for the purpose of ascertaining the entitlement is February 24, 2022.
7. Based on the internal and external information available up to the date of approval of these financial results by the Board of Directors, the Company continues to believe that the impact of Covid-19 on its business, assets, internal financial controls, profitability and liquidity, both present and future, would be limited and there is no indication of any material impact on the carrying amounts of inventories, tangible and intangible assets, investments, trade receivables and other financial assets. However, concerns of Covid-19 pandemic still continue and hence, the Company continues to follow necessary safety guidelines. The eventual outcome of the impact of the global health pandemic may be different from those estimated as on the date of approval of these financial results and the management will continue to closely monitor the changes to economic conditions in future and its impact on the Company.
8. The Company has only one reportable business segment viz. "Pharmaceuticals".
9. The figures for the previous period(s) have been re-grouped/reclassified, wherever necessary.

EM RKU

Mumbai  
14th February, 2022

By order of the Board  
For J.B. Chemicals & Pharmaceuticals Limited

Nikhil Chopra  
Chief Executive Officer & Whole-time Director

### Registered Office:


Neelam Centre, B Wing, 4th Floor  
Hind Cycle Road, Worli  
Mumbai - 400 030

### Corporate Office:

Energy IT Park 2/2  
Unit A2, 3rd Floor, Unit A, 8th Floor  
Appa Saheb Marathe Marg, Prabhadevi  
Mumbai - 400 025

☎ +91 22 2439 5200 / 2439 5500  
☎ +91 22 2431 5331 / 2431 5334  
✉ [info@jbcpl.com](mailto:info@jbcpl.com)  
🌐 [www.jbcpl.com](http://www.jbcpl.com)  
CIN: L24390MH1976PLC019380





# J. B. CHEMICALS & PHARMACEUTICALS LIMITED

STATEMENT OF CONSOLIDATED UNAUDITED FINANCIAL RESULTS FOR THE QUARTER AND NINE MONTHS ENDED 31ST DECEMBER, 2021

(₹ in lakhs)

Particulars	Quarter ended			Nine months ended		Year ended
	31/12/2021	30/09/2021	31/12/2020	31/12/2021	31/12/2020	31/03/2021
	Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited
1. Revenue from operations	60,065.60	59,301.17	54,821.69	1,79,965.62	1,51,406.62	2,04,252.15
2. Other income (Refer note 3)	452.78	1,964.41	5,595.25	3,714.61	8,703.48	11,238.32
3. Total income (1+2)	60,518.38	61,265.58	60,416.94	1,83,680.23	1,60,110.10	2,15,490.47
4. Expenses						
a) Cost of materials consumed	14,659.71	14,721.86	12,853.76	44,174.54	40,722.15	54,238.96
b) Purchases of stock-in-trade	5,273.32	6,645.22	5,959.61	19,723.85	16,024.05	20,036.65
c) Changes in inventories of finished goods, work-in-progress and stock-in-trade	670.17	(613.62)	(124.28)	(887.47)	(6,048.66)	(4,125.71)
d) Employee benefits expense (Refer note 4)	11,947.06	10,540.31	8,469.83	32,301.35	25,443.57	34,060.09
e) Finance costs	134.12	122.45	109.10	350.51	655.19	724.12
f) Depreciation and amortisation expense	1,696.90	1,573.37	1,739.28	5,055.16	5,213.31	6,866.55
g) Other expenses	14,704.58	15,333.25	10,563.45	42,800.21	31,614.16	44,001.27
Total expenses	49,085.86	48,322.84	39,570.75	1,43,518.15	1,13,623.77	1,55,801.93
5. Profit before tax (3-4)	11,432.52	12,942.74	20,846.19	40,162.08	46,486.33	59,688.54
6. Tax expense						
a) Current tax	2,919.43	2,744.59	4,968.24	9,606.63	11,222.56	14,220.32
b) Deferred tax	101.35	409.39	449.55	449.01	492.48	615.92
Total tax expense	3,020.78	3,153.98	5,417.79	10,055.64	11,715.04	14,836.24
7. Net profit after tax (5-6)	8,411.74	9,788.76	15,428.40	30,106.44	34,771.29	44,852.30
8. Other comprehensive income						
a) (i) Items that will not be reclassified to profit or loss	(210.00)	(211.43)	(724.63)	(633.98)	(1,336.07)	(1,669.97)
(ii) Income tax on items that will not be reclassified to profit or loss	52.85	53.22	182.37	159.56	336.26	420.30
b) (i) Items that will be reclassified to profit or loss	(484.00)	(570.41)	1,402.66	(561.70)	1,603.12	1,283.13
(ii) Income tax on items that will be reclassified to profit or loss	(33.51)	-	-	(33.51)	-	-
Total other comprehensive income (net of tax)	(674.66)	(728.62)	860.40	(1,069.63)	603.31	33.46
9. Total comprehensive income after tax (7+8)	7,737.08	9,060.14	16,288.80	29,036.81	35,374.60	44,885.76
10. Net Profit after tax for the period/year attributable to :						
a) Owners of the company	8,388.60	9,775.31	15,410.66	30,051.23	34,735.10	44,796.36
b) Non-controlling interest	23.14	13.45	17.74	55.21	36.19	55.94
11. Other comprehensive income for the period attributable to :						
a) Owners of the company	(651.07)	(704.89)	810.80	(1,036.98)	535.27	(31.01)
b) Non-controlling interest	(23.59)	(23.73)	49.60	(32.65)	68.04	64.47
12. Total comprehensive income after tax attributable to :						
a) Owners of the company	7,737.53	9,070.42	16,221.46	29,014.25	35,270.37	44,765.35
b) Non-controlling interest	(0.45)	(10.28)	67.34	22.56	104.23	120.41
13. Paid-up equity share capital (face value ₹ 2/- each)	1,545.64	1,545.64	1,545.64	1,545.64	1,545.64	1,545.64
14. Other equity						1,79,426.84
15. Earnings per share (face value ₹ 2/- each)						
a) Basic (₹)	*10.85	*12.65	*19.94	*38.89	*44.95	57.96
b) Diluted (₹)	*10.82	*12.63	*19.94	*38.80	*44.95	57.96
*Not Annualised						

Registered Office:  
Neelam Centre, B Wing, 4th Floor  
Hind Cycle Road, Worli  
Mumbai - 400 030

Corporate Office:  
Energy IT Park 1/2  
Unit A2, 3rd Floor, Unit A, 8th Floor  
Appa Saheb Marathe Marg, Prabhadevi  
Mumbai - 400 025

+91 22 2439 5200 / 2439 5500  
+91 22 2431 5331 / 2431 5334  
info@jbcpl.com  
www.jbcpl.com  
CIN: L24390MH1976PLC019380



# J. B. CHEMICALS & PHARMACEUTICALS LIMITED

## Notes:

1. The above consolidated financial results have been reviewed and recommended to the Board of Directors by the Audit Committee and subsequently approved by the Board of Directors at their respective meetings held on 14th February, 2022. These results have been subjected to Limited review by the Statutory auditors of the Company. The results of the Company are available for investors at [www.jbcpl.com](http://www.jbcpl.com), [www.nseindia.com](http://www.nseindia.com) and [www.bseindia.com](http://www.bseindia.com).
2. These financial results have been prepared in accordance with the recognition and measurement principles laid down in the Companies (Indian Accounting Standards) Rules 2015 (as amended) ('Ind AS') prescribed under Section 133 of the Companies Act, 2013 read with relevant rules thereunder and in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended). The consolidated financial results of the Holding Company, its wholly owned subsidiaries and a step-down subsidiary ("the Group") have been prepared by applying Ind AS 110 on Consolidated Financial Statements.
3. Other income for the year ended March 31, 2021 includes ₹1,977.24 lakhs being net profit on sale of an industrial land in the state of Maharashtra of the Holding Company and ₹ 3,368.66 lakhs being consideration towards sale of one of the Holding Company's product registration along with its marketing authorisation and trademark.
4. During the quarter, the Holding Company has granted 2,06,463 stock options (comprising of 1,21,095 performance based stock options and 85,368 time based stock options) to employees of the Holding Company/ Subsidiary Company. With these grants the total options granted stand at 28,10,721 stock options (comprising of 15,72,761 performance based stock options and 12,37,960 time based stock options) to employees and whole-time director(s) of the Holding Company/ subsidiary company. The employee benefits expense for the quarters ended December 31, 2021 and September 30, 2021 and for the nine months ended December 31, 2021 includes charge of ₹2,513 lakhs, ₹1,316 lakhs and ₹3,829 lakhs respectively, towards equity-settled share-based payment transactions in terms of Ind AS 102 - 'Share-based Payment'.
5. Non-adjusting event subsequent to the reporting period: On January 25, 2022, the Board of Directors of the Holding Company approved the acquisition of a portfolio of brands, for use and commercialisation within India, from Sanzyme Private Limited . The transaction was completed on February 1, 2022.
6. The Board of Directors of the Holding Company, at its meeting held today, have declared an interim dividend of ₹8.50 per equity share of ₹2 each for the year 2021-22. The record date for the purpose of ascertaining the entitlement is February 24, 2022.
7. Based on the internal and external information available up to the date of approval of these financial results by the Board of Directors, the Group continues to believe that the impact of Covid-19 on its business, assets, internal financial controls, profitability and liquidity, both present and future, would be limited and there is no indication of any material impact on the carrying amounts of inventories, tangible and intangible assets, investments, trade receivables and other financial assets. However, concerns of Covid-19 pandemic still continue and hence, the Group continues to follow necessary safety guidelines. The eventual outcome of the impact of the global health pandemic may be different from those estimated as on the date of approval of these financial results and the management will continue to closely monitor the changes to economic conditions in future and its impact on the Group.
8. The Group has only one reportable business segment viz. "Pharmaceuticals".
9. The figures for the previous period(s) have been re-grouped/reclassified, wherever necessary.

By order of the Board  
For J.B. Chemicals & Pharmaceuticals Limited

**Nikhil Chopra**

Chief Executive Officer & Whole-time Director

Mumbai  
14th February, 2022

### Registered Office:

Neelam Centre, B Wing, 4th Floor  
Hind Cycle Road, Worli  
Mumbai - 400 030

### Corporate Office:

Energy IT Park 2/2  
Unit A2, 3rd Floor, Unit A, 8th Floor  
Appa Saheb Marathe Marg, Prabhadevi  
Mumbai - 400 025

+91 22 2439 5200 / 2439 5500

+91 22 2431 5331 / 2431 5334

info@jbcpl.com

www.jbcpl.com

CIN: L24390MH1976PLC019380



**INDEPENDENT AUDITOR'S REVIEW REPORT ON REVIEW OF INTERIM CONSOLIDATED FINANCIAL RESULTS**

**TO THE BOARD OF DIRECTORS OF  
J. B. CHEMICALS & PHARMACEUTICALS LIMITED**

1. We have reviewed the accompanying Statement of Consolidated Unaudited Financial Results of **J. B. CHEMICALS & PHARMACEUTICALS LIMITED** ("the Parent") and its subsidiaries (the Parent and its subsidiaries together referred to as "the Group"), for the quarter and nine months ended December 31, 2021 ("the Statement") being submitted by the Parent pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended.
2. This Statement, which is the responsibility of the Parent's Management and approved by the Parent's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other accounting principles generally accepted in India. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India (ICAI). A review of interim financial information consists of making inquiries, primarily of Parent's personnel responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing specified under Section 143(10) of the Companies Act, 2013 and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

We also performed procedures in accordance with the circular issued by the SEBI under Regulation 33(8) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, to the extent applicable.

4. The Statement includes the results of the following entities:  
Parent                                      J. B. Chemicals & Pharmaceuticals Limited

Direct Subsidiaries      OOO Unique Pharmaceutical Laboratories; and  
Unique Pharmaceutical Laboratories FZE.

Step down Subsidiary    Biotech Laboratories (Pty.) Ltd.

5. Based on our review conducted and procedures performed as stated in paragraph 3 above, and based on the consideration of the review report of the other auditor referred to in paragraph 6 below, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standard and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and

*EA RKV*

# Deloitte Haskins & Sells LLP

Disclosure Requirements) Regulations, 2015, as amended, including the manner in which it is to be disclosed, or that it contains any material misstatement.

6. We did not review the interim financial information of one subsidiary included in the consolidated unaudited financial results, whose interim financial information reflect total revenues of Rs. 8,566.61 Lakhs and Rs. 22,644.81 Lakhs for the quarter and nine months ended December 31, 2021 respectively, total net profit after tax of Rs. 486.25 Lakhs and Rs. 1,159.93 Lakhs for the quarter and nine months ended December 31, 2021 respectively and total comprehensive income of Rs. 486.25 Lakhs and Rs. 1,159.93 Lakhs for the quarter and nine months ended December 31, 2021 respectively, as considered in the Statement. This interim financial information has been reviewed by another auditor whose report has been furnished to us and our conclusion on the Statement, in so far as it relates to the amounts and disclosures included in respect of this subsidiary, is based solely on the report of the other auditor and the procedures performed by us as stated in paragraph 3 above.

Our conclusion on the Statement is not modified in respect of this matter.

7. The consolidated unaudited financial results include the interim financial information of two subsidiaries which have not been reviewed by their auditors, whose interim financial information reflect total revenues of Rs. 2,634.16 Lakhs and Rs. 5,720.46 Lakhs for the quarter and nine months ended December 31, 2021 respectively, total net profit after tax of Rs. 53.11 Lakhs and Rs. 65.82 Lakhs for the quarter and nine months ended December 31, 2021 respectively and total comprehensive income of Rs. 53.11 Lakhs and Rs. 65.82 Lakhs for the quarter and nine months ended December 31, 2021, as considered in the Statement. According to the information and explanations given to us by the Management, these interim financial information are not material to the Group.

Our conclusion on the Statement is not modified in respect of our reliance on the interim financial information certified by the Management.

For DELOITTE HASKINS & SELLS LLP  
Chartered Accountants  
(Firm's Registration No. 117366W/W-100018)



Rajesh K. Hiranandani  
Partner  
(Membership No.36920)  
(UDIN: 22036920ACACNR4019)



Place: MUMBAI  
Date: February 14, 2022





# J. B. CHEMICALS & PHARMACEUTICALS LIMITED

STATEMENT OF CONSOLIDATED UNAUDITED FINANCIAL RESULTS FOR THE QUARTER AND NINE MONTHS ENDED 31ST DECEMBER, 2021

(₹ in lakhs)

Particulars	Quarter ended			Nine months ended		Year ended
	31/12/2021	30/09/2021	31/12/2020	31/12/2021	31/12/2020	31/03/2021
	Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited
1. Revenue from operations	60,065.60	59,301.17	54,821.69	1,79,965.62	1,51,406.62	2,04,252.15
2. Other income (Refer note 3)	452.78	1,964.41	5,595.25	3,714.61	8,703.48	11,238.32
3. Total income (1+2)	60,518.38	61,265.58	60,416.94	1,83,680.23	1,60,110.10	2,15,490.47
4. Expenses						
a) Cost of materials consumed	14,659.71	14,721.86	12,853.76	44,174.54	40,722.15	54,238.96
b) Purchases of stock-in-trade	5,273.32	6,645.22	5,959.61	19,723.85	16,024.05	20,036.65
c) Changes in inventories of finished goods, work-in-progress and stock-in-trade	670.17	(613.62)	(124.28)	(887.47)	(6,048.66)	(4,125.71)
d) Employee benefits expense (Refer note 4)	11,947.06	10,540.31	8,469.83	32,301.35	25,443.57	34,060.09
e) Finance costs	134.12	122.45	109.10	350.51	655.19	724.12
f) Depreciation and amortisation expense	1,696.90	1,573.37	1,739.28	5,055.16	5,213.31	6,866.55
g) Other expenses	14,704.58	15,333.25	10,563.45	42,800.21	31,614.16	44,001.27
Total expenses	49,085.86	48,322.84	39,570.75	1,43,518.15	1,13,623.77	1,55,801.93
5. Profit before tax (3-4)	11,432.52	12,942.74	20,846.19	40,162.08	46,486.33	59,688.54
6. Tax expense						
a) Current tax	2,919.43	2,744.59	4,968.24	9,606.63	11,222.56	14,220.32
b) Deferred tax	101.35	409.39	449.55	449.01	492.48	615.92
Total tax expense	3,020.78	3,153.98	5,417.79	10,055.64	11,715.04	14,836.24
7. Net profit after tax (5-6)	8,411.74	9,788.76	15,428.40	30,106.44	34,771.29	44,852.30
8. Other comprehensive income						
a) (i) Items that will not be reclassified to profit or loss	(210.00)	(211.43)	(724.63)	(633.98)	(1,336.07)	(1,669.97)
(ii) Income tax on items that will not be reclassified to profit or loss	52.85	53.22	182.37	159.56	336.26	420.30
b) (i) Items that will be reclassified to profit or loss	(484.00)	(570.41)	1,402.66	(561.70)	1,603.12	1,283.13
(ii) Income tax on items that will be reclassified to profit or loss	(33.51)	-	-	(33.51)	-	-
Total other comprehensive income (net of tax)	(674.66)	(728.62)	860.40	(1,069.63)	603.31	33.46
9. Total comprehensive income after tax (7+8)	7,737.08	9,060.14	16,288.80	29,036.81	35,374.60	44,885.76
10. Net Profit after tax for the period/year attributable to :						
a) Owners of the company	8,388.60	9,775.31	15,410.66	30,051.23	34,735.10	44,796.36
b) Non-controlling interest	23.14	13.45	17.74	55.21	36.19	55.94
11. Other comprehensive income for the period attributable to :						
a) Owners of the company	(651.07)	(704.89)	810.80	(1,036.98)	535.27	(31.01)
b) Non-controlling interest	(23.59)	(23.73)	49.60	(32.65)	68.04	64.47
12. Total comprehensive income after tax attributable to :						
a) Owners of the company	7,737.53	9,070.42	16,221.46	29,014.25	35,270.37	44,765.35
b) Non-controlling interest	(0.45)	(10.28)	67.34	22.56	104.23	120.41
13. Paid-up equity share capital (face value ₹ 2/- each)	1,545.64	1,545.64	1,545.64	1,545.64	1,545.64	1,545.64
14. Other equity						1,79,426.84
15. Earnings per share (face value ₹ 2/- each)						
a) Basic (₹)	*10.85	*12.65	*19.94	*38.89	*44.95	57.96
b) Diluted (₹)	*10.82	*12.63	*19.94	*38.80	*44.95	57.96

\*Not Annualised

EM RKU

Registered Office:

Neelam Centre, B Wing, 4th Floor  
Hind Cycle Road, Worli  
Mumbai - 400 030

Corporate Office:

Energy IT Park 1/2  
Unit A2, 3rd Floor, Unit A 8th Floor  
Appa Saheb Marathe Marg, Prabhadevi  
Mumbai - 400 025

+91 22 2439 5200 / 2439 5500

+91 22 2431 5331 / 2431 5334

info@jbcpl.com

www.jbcpl.com

CIN: L24390MH1976PLC019380

*Signature*



# J. B. CHEMICALS & PHARMACEUTICALS LIMITED

## Notes:

1. The above consolidated financial results have been reviewed and recommended to the Board of Directors by the Audit Committee and subsequently approved by the Board of Directors at their respective meetings held on 14th February, 2022. These results have been subjected to limited review by the Statutory auditors of the Company. The results of the Company are available for investors at [www.jbcpl.com](http://www.jbcpl.com), [www.nseindia.com](http://www.nseindia.com) and [www.bseindia.com](http://www.bseindia.com).
2. These financial results have been prepared in accordance with the recognition and measurement principles laid down in the Companies (Indian Accounting Standards) Rules 2015 (as amended) ('Ind AS') prescribed under Section 133 of the Companies Act, 2013 read with relevant rules thereunder and in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended). The consolidated financial results of the Holding Company, its wholly owned subsidiaries and a step-down subsidiary ("the Group") have been prepared by applying Ind AS 110 on Consolidated Financial Statements.
3. Other income for the year ended March 31, 2021 includes ₹1,977.24 lakhs being net profit on sale of an industrial land in the state of Maharashtra of the Holding Company and ₹ 3,368.66 lakhs being consideration towards sale of one of the Holding Company's product registration along with its marketing authorisation and trademark.
4. During the quarter, the Holding Company has granted 2,06,463 stock options (comprising of 1,21,095 performance based stock options and 85,368 time based stock options) to employees of the Holding Company/ Subsidiary Company. With these grants the total options granted stand at 28,10,721 stock options (comprising of 15,72,761 performance based stock options and 12,37,960 time based stock options) to employees and whole-time director(s) of the Holding Company/ subsidiary company. The employee benefits expense for the quarters ended December 31, 2021 and September 30, 2021 and for the nine months ended December 31, 2021 includes charge of ₹2,513 lakhs, ₹1,316 lakhs and ₹3,829 lakhs respectively, towards equity-settled share-based payment transactions in terms of Ind AS 102 - 'Share-based Payment'.
5. Non-adjusting event subsequent to the reporting period: On January 25, 2022, the Board of Directors of the Holding Company approved the acquisition of a portfolio of brands, for use and commercialisation within India, from Sanzyme Private Limited. The transaction was completed on February 1, 2022.
6. The Board of Directors of the Holding Company, at its meeting held today, have declared an interim dividend of ₹8.50 per equity share of ₹2 each for the year 2021-22. The record date for the purpose of ascertaining the entitlement is February 24, 2022.
7. Based on the internal and external information available up to the date of approval of these financial results by the Board of Directors, the Group continues to believe that the impact of Covid-19 on its business, assets, internal financial controls, profitability and liquidity, both present and future, would be limited and there is no indication of any material impact on the carrying amounts of inventories, tangible and intangible assets, investments, trade receivables and other financial assets. However, concerns of Covid-19 pandemic still continue and hence, the Group continues to follow necessary safety guidelines. The eventual outcome of the impact of the global health pandemic may be different from those estimated as on the date of approval of these financial results and the management will continue to closely monitor the changes to economic conditions in future and its impact on the Group.
8. The Group has only one reportable business segment viz. "Pharmaceuticals".
9. The figures for the previous period(s) have been re-grouped/reclassified, wherever necessary.

EM RKU

Mumbai  
14th February, 2022

By order of the Board  
For J.B. Chemicals & Pharmaceuticals Limited

**Nikhil Chopra**  
Chief Executive Officer & Whole-time Director

### Registered Office:

Neelam Centre, B Wing, 4th Floor  
Hind Cycle Road, Worli  
Mumbai - 400 030

### Corporate Office:

Energy IT Park 2/2  
Unit A2, 3rd Floor, Unit A, 8th Floor  
Appa Saheb Marathe Marg, Prabhadevi  
Mumbai - 400 025

☎ +91 22 2439 5200 / 2439 5500  
☎ +91 22 2431 5331 / 2431 5334  
@ [info@jbcpl.com](mailto:info@jbcpl.com)  
🌐 [www.jbcpl.com](http://www.jbcpl.com)  
CIN: L24390MH1976PLC019380